and NexGard Spectra™ (afoxolaner and milbemycin oxime) to include an indication for the reduction of B. burgdorferi infections as a direct result of killing adult I. scapularis vector ticks.

NexGard Spectra, a prescription-only product, has been approved in Europe for the treatment of flea and tick infestations, the prevention of heartworm disease and/or the treatment of intestinal ...

NexGard and NexGard SPECTRA are already indicated to fight eight species of ticks that afflict dogs. The new claim concerns indication against Ixodes hexagonus tick, reported from most European ...

Boehringer Ingelheim, a global leader in animal health, announced the launch of NexGard Spectra (afoxolaner and milbemycin oxime) in India, following its approval by the Central Drugs Standard Control ...